Biotech Values

[masterlongevity]

a quote from this article and my thoughts on it..

"If you look at things by therapeutic area, oncology has the roughest row to hoe with over 93% failure. Its failure rate is still over 50% in Phase III, which is particularly hair-raising. "

I dont think this is only because oncology is "harder". A lot of it has to do with what Dew has pointed out on here. There are a ton of compounds in development (compared to other disease areas), and a lot of them are very low quality programs. Companies tend to do less chasing in other areas, and dont force as many low quality compounds into ph 3